Which are the symptoms of Hunter syndrome?

Hunter syndrome, or Mucopolysaccharidosis type II (MPS II), is a progressive multisystem disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of glycosaminoglycans (GAGs). Symptoms typically manifest in early childhood, ranging from coarse facial features and skeletal abnormalities to neurological decline, with severity highly dependent on whether the disease is neuronopathic (severe) or non-neuronopathic (attenuated).

What are the primary symptoms of Hunter syndrome?

Because Hunter syndrome is a systemic condition, symptoms vary widely between patients. The accumulation of GAGs affects nearly every organ system. Common clinical presentations observed in our 66 DiseaseMaps community members include:

• Physical changes: Coarse facial features, macrocephaly (enlarged head), and thickened skin.


• Skeletal issues: Joint stiffness, restricted range of motion, and dysostosis multiplex (abnormal bone development).


• Organ enlargement: Hepatosplenomegaly (enlarged liver and spleen), which often causes abdominal distension.


• Respiratory and ENT: Chronic ear infections, recurring respiratory infections, and obstructive sleep apnea.


• Neurological impact: Developmental delays and, in severe cases, progressive cognitive decline and behavioral challenges.

How does Hunter syndrome progress over time?

Hunter syndrome is a progressive disease, meaning symptoms worsen as GAGs continue to accumulate. In early childhood, parents may first notice "warning signs" such as persistent umbilical or inguinal hernias, chronic runny noses, or a characteristic "claw-hand" deformity. While physical symptoms progress in both forms, the severe phenotype is distinguished by the onset of neurological regression, usually occurring between ages 2 and 4, which significantly impacts daily quality of life and long-term independence.

When should families seek immediate medical attention?

Due to the multisystem nature of Hunter syndrome, immediate medical evaluation is necessary if a patient experiences acute respiratory distress, sudden loss of developmental milestones, or signs of spinal cord compression. Given the risk of cardiac involvement, such as valvular heart disease, regular monitoring by a multidisciplinary team is essential to manage complications before they become life-threatening.

Next steps

• Consult a metabolic specialist or geneticist to confirm the diagnosis via enzyme assay or genetic testing.


• Connect with the 66 members of the Hunter syndrome community on DiseaseMaps.org to share experiences.


• Discuss enzyme replacement therapy (ERT) or clinical trial opportunities with your clinical team.


• Schedule regular screenings with cardiologists, pulmonologists, and neurologists.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hunter syndrome


• Orphanet: Mucopolysaccharidosis type II


• OMIM (Online Mendelian Inheritance in Man): Iduronate-2-sulfatase deficiency


• National MPS Society: Hunter syndrome patient resources